Scienmag
MARCH 3, 2021
Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.
pharmaphorum
SEPTEMBER 29, 2022
The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain. The post FDA clears Dupixent as first drug for rare skin disorder appeared first on.
The Pharma Data
APRIL 28, 2021
These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.
Expert insights. Personalized for you.
57 
Let's personalize your content